Expedeon : 4basebio AG announces process for spin-off and separate stock market listing for its DNA business

Ad hoc Release according to Art. 17 Market Abuse Regulation

4basebio AG announces process for spin-off and separate stock market listing for its DNA business

Heidelberg, Germany, and Cambridge, UK, 17 August 2020 - Following a strategic review, 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Stand- ard) today announces its intention to commence a process to spin off its whole operating busi- ness, namely the Genomics and DNA manufacturing business which includes 4basebio SLU and 4basebio Ltd. Subject to an ongoing legal and tax review, a spin-off of the business into a separate company is intended which shall have its corporate seat in the UK and be listed on the Alternative Investment Market (AIM), a submarket of the London Stock Exchange market. 4basebio AG is considering retaining a significant minority stake in the new entity and distributing the remaining shares to its existing shareholders. As part of this process, 4basebio AG will ensure the spin-off is suitably capitalised from the existing cash of 4basebio AG. The management board of 4basebio AG would join the board of the spin-off and assume responsibility for the day to day operation of this organisation. As a result of the planed process, 4basebio AG would in addition to its participation in the new company still hold a significant cash position. The intention is to complete this core process by 31 December 2020.

The company will continue to keep its shareholders updated during this process.

*** end of ad hoc announcement ***

For further information, please contact:

4basebio AG

Dr. Heikki Lanckriet

CEO/CSO

Phone: [phone]

Email:[e-mail]

Investors' information: investors.4basebio.com

MC Services AG (Investor Relations and International Media Relations)

Julia Hofmann

Page 2

Phone: [phone]

Email:[e-mail]

• This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predic- tions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###